This certification validates the plant’s robust capabilities in manufacturing a wide range of sterile dosage forms
This GMP certification for our sterile drug product manufacturing facility, Goa Plant II is a testament to our relentless efforts to supply quality and affordable medicines across geographies
The scheme aims to avoid disruption in supply of critical active pharmaceutical ingredients (APIs) used to make critical drugs
Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately $10 billion invested to date
Enables additional US manufacturing capacity to serve increased demand for pharma/biotech customers
Commercial production is expected to begin soon
Extended lab space for product development, customer demos, and training
The GMP-compliant facility with automated environmental monitoring accommodates both white room and class 7 and 8 cleanroom space
The company received one observation in the Form-483
The project will be instrumental in enhancing the company's API manufacturing capacity and global reach
Subscribe To Our Newsletter & Stay Updated
